Volume 124, Issue 11 pp. 2616-2620
Tumor Immunology

Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma

Robert J. Biggar

Corresponding Author

Robert J. Biggar

Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

Fax: 45-32-38-31-65.

Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen, DenmarkSearch for more papers by this author
Michael Christiansen

Michael Christiansen

Department of Clinical Biochemistry, Statens Serum Institut, Copenhagen, Denmark

Search for more papers by this author
Klaus Rostgaard

Klaus Rostgaard

Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

Search for more papers by this author
Karin Ekström Smedby

Karin Ekström Smedby

Department of Medicine, Clinical Epidemiology Unit, Karolinska University Hospital, Stockholm, Sweden

Search for more papers by this author
Hans-Olov Adami

Hans-Olov Adami

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

Department of Epidemiology, Harvard School of Public Health and Dana Farber/Harvard Cancer Center, Boston, MA

Search for more papers by this author
Bengt Glimelius

Bengt Glimelius

Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Uppsala, Sweden

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden

Search for more papers by this author
Henrik Hjalgrim

Henrik Hjalgrim

Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

Search for more papers by this author
Mads Melbye

Mads Melbye

Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

Search for more papers by this author
First published: 25 March 2009
Citations: 30

Abstract

Allergy/atopy has been suggested to protect against non-Hodgkin lymphoma (NHL) and specific IgE levels are decreased in patients with NHL. We speculated that all immunoglobulin subclass levels might be downregulated in NHL and examined levels of IgM, IgD, IgA, IgE, IgG and IgG4 in 200 NHL patients and 200 age- and sex-matched controls. Patients with B-cell NHL of many types had consistently lower median immunoglobulin subclass levels than controls. In every subclass except IgD, about 10–15% of B-cell NHL patients had absolute levels below the 2.5 percentile of controls. Subclass levels correlated with each other and many patients had more than one significantly low level. Levels were lowest for IgG4 and IgE. Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma had especially low total IgE levels. In other B-cell NHL types, total IgE levels were decreased to a similar extent as other immunoglobulin subclasses. In conclusion, low IgE levels are only part of a more generalized loss of immunoglobulins of all subtypes in a wide variety of B-cell NHL types. Low immunoglobulin levels appear to be a consequence of B-cell NHL presence, and we speculate about molecular mechanisms that could reduce all immunoglobulin subclasses in B-cell NHL. © 2008 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.